HeimAPNHY • OTCMKTS
add
Aspen Pharmacare Holdings ADR
Við síðustu lokun
9,42 $
Dagbil
9,65 $ - 9,65 $
Árabil
9,42 $ - 13,69 $
Markaðsvirði
75,89 ma. ZAR
Meðalmagn
174,00
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (ZAR) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 11,78 ma. | 9,30% |
Rekstrarkostnaður | 2,36 ma. | -3,24% |
Nettótekjur | 1,04 ma. | -18,17% |
Hagnaðarhlutfall | 8,87 | -25,15% |
Hagnaður á hvern hlut | — | — |
EBITDA | 2,93 ma. | 7,80% |
Virkt skatthlutfall | 25,52% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (ZAR) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 12,34 ma. | 13,06% |
Heildareignir | 139,16 ma. | 3,63% |
Heildarskuldir | 54,29 ma. | 13,00% |
Eigið fé alls | 84,86 ma. | — |
Útistandandi hlutabréf | 444,21 m. | — |
Eiginfjárgengi | 0,05 | — |
Arðsemi eigna | 4,84% | — |
Ávöxtun eigin fjár | 5,56% | — |
Peningaflæði
Breyting á handbæru fé
| (ZAR) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,04 ma. | -18,17% |
Handbært fé frá rekstri | 1,88 ma. | -1,21% |
Reiðufé frá fjárfestingum | -1,65 ma. | -79,92% |
Reiðufé frá fjármögnun | -141,50 m. | 52,91% |
Breyting á handbæru fé | -200,00 m. | -118,37% |
Frjálst peningaflæði | 525,31 m. | -32,86% |
Um
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
Framkvæmdastjóri
Stofnsett
1850
Höfuðstöðvar
Vefsvæði
Starfsfólk
9.109
